Page last updated: 2024-12-11
aconiazide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5391612 |
| MeSH ID | M0091356 |
Synonyms (19)
| Synonym |
|---|
| aconiazide |
| aconiazidum [inn-latin] |
| brn 0300804 |
| isonicotinic acid, (o-(carboxymethoxy)benzylidene)hydrazide |
| phenoxalid |
| compound 377 |
| 4-pyridinecarboxylic acid, ((2-(carboxymethoxy)phenyl)methylene)hydrazide |
| aconiazida [inn-spanish] |
| isonicotinic acid (o-(carboxymethoxy)benzylidene)hydrazide |
| o-(isonicotinoylhydrazonomethinyl)phenoxyessigsaeure |
| aconiazide [inn] |
| 2-[2-[(z)-(pyridine-4-carbonylhydrazinylidene)methyl]phenoxy]acetic acid |
| unii-8okq9ns8mo |
| 13410-86-1 |
| aconiazidum |
| aconiazida |
| 8okq9ns8mo , |
| 4-22-00-00585 (beilstein handbook reference) |
| Q15633956 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "Identifying the maximum safe dose (MAXSD) is an objective of both randomized clinical dose-finding studies for the safety endpoint and toxicological studies." | ( Identifying the maximum safe dose: a multiple testing approach. Hauschke, D; Hothorn, LA, 2000) | 0.31 |
Bioavailability
aconiazide's relative bioavailability (based on the area under the serum concentration-time curve) was 50. Compared with isoniazid tablets, aconiaZide's Relative Bioavailability (Based on the Area Under The Serum Concentration-time Curve) was 40.
| Excerpt | Reference | Relevance |
|---|---|---|
| "To determine the bioavailability and renal elimination of isoniazid, acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, aconiazide, and 2-formylphenoxyacetic acid." | ( Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid prodrug. Craig, LD; Iklé, D; Iseman, MD; James, GT; Kim, M; McCarthy, EA; Peloquin, CA, ) | 0.63 |
| " Compared with isoniazid tablets, aconiazide's relative bioavailability (based on the area under the serum concentration-time curve) was 50." | ( Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid prodrug. Craig, LD; Iklé, D; Iseman, MD; James, GT; Kim, M; McCarthy, EA; Peloquin, CA, ) | 0.7 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The methods are illustrated with data from a dose-response study, and their performance is evaluated with a Monte Carlo simulation study." | ( Upper confidence limits on excess risk for quantitative responses. Kodell, RL; West, RW, 1993) | 0.29 |
| "Reversed-phase HPLC methods are described for determining the stability and concentration certification of the antituberculosis prodrug aconiazide (ACON) in aqueous dosing solution and for assessing the concentrations of ACON and isoniazid (INH) in plasma from ACON-treated male and female Fischer-344 rats." | ( High-performance liquid chromatographic analysis of the antituberculosis drugs aconiazide and isoniazid. Dooley, KL; Hansen, EB; Thompson, HC, 1995) | 0.72 |
| " Although risk-assessment procedures that attempt to utilize the quantitative information in such data have been proposed, there is no general agreement that these procedures are appreciably more efficient than common quantal dose-response procedures that operate on dichotomized continuous data." | ( A comparison of methods of benchmark-dose estimation for continuous response data. Kodell, RL; West, RW, 1999) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.98
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.98) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||